ADRX-0134 / Adcentrx Therap - LARVOL DELTA

ADRX-0134 as a novel auristatin-based NaPi2b antibody-drug conjugate with widened therapeutic window (AACR 2025) - "Based on this differential expression profile, a proof-of-concept for an antibody-drug conjugate (ADC) approach utilizing NaPi2b was achieved with lifastuzumab vedotin and upifitamab rilsodotin. Here, the stable TK profile ensured minimal and recoverable hematology findings, an unchanged clinical chemistry profile and normal histology of lung, liver, GI and eye, which were key safety liabilities for other NaPi2b ADCs. In summary, ADRX-0134 exhibits excellent biophysical features with highly selective and increased efficacy in NaPi2b-expressing tumors, while being well-tolerated in cynomolgus monkeys at doses that are expected to provide a widened therapeutic window over first-generation NaPi2b ADCs."

Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • SLC34A2

Adcentrx Therapeutics to Showcase Novel STEAP1 and NaPi2b ADCs with Oral and Poster Presentations at AACR 2025 (PRNewswire) - "Adcentrx Therapeutics...will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2025....The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical NaPi2b ADC. The presentations will underscore the versatility of Adcentrx's ADC platform, showing advancements in therapeutic window expansion, bystander effect optimization, and payload delivery improvements for targeted cancer therapy."

Preclinical • Castration-Resistant Prostate Cancer